Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

171624 items
12:27 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Other News

Cellectis granted U.S. patents for CRISPR T cell therapies

The U.S. Patent Office granted Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) two patents covering the use of RNA-guided endonucleases to develop T cell immunotherapies. Both patents claim methods of editing T cells using transient expression of CRISPR/nuclease components....
12:26 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Gilead picks Sangamo's ZFN gene editing for cell therapies

Sangamo Therapeutics Inc. (NASDAQ:SGMO) partnered with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV) technology to develop next-generation autologous and allogeneic cell...
12:26 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Arcus proposes $100M IPO

Cancer immunotherapy company Arcus Biosciences Inc. (Hayward, Calif.) proposed on Feb. 16 to raise $100 million in an IPO on NYSE underwritten by Citigroup, Goldman Sachs and Leerink. Arcus Biosciences Inc., Hayward, Calif.  ...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Ascendis raises $225M in bumped-up follow-on

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) raised $225 million on Feb. 22 through the sale of 3.9 million ADSs at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse, Wells...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Aimmune raises $176M in bumped up follow-on

Allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised $176 million on Feb. 22 through the sale of 5.5 million shares at $32 in a bumped-up follow-on. Underwriters were BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Ra raises $50.4M in follow-on

Complement-mediated disease company Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $50.4 million on Feb. 14 through the sale of 8.4 million shares at $6 in a follow-on underwritten by Credit Suisse, Jefferies, BMO Capital Markets and SunTrust...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Pieris raises $50.6M in follow-on

Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares at $8 in a follow-on underwritten by Jefferies, Cowen and Evercore ISI. The figures include the sale of an...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Pacific raises $30M in follow-on

Sequencing company Pacific Biosciences of California Inc. (NASDAQ:PACB) raised $30 million on Feb. 13 through the sale of 12.5 million shares at $2.40 in a follow-on underwritten by Cantor. The price is a 6% discount to...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

miRagen raises $38.5M in follow-on

MicroRNA company miRagen Therapeutics Inc. (NASDAQ:MGEN) raised $38.5 million on Feb. 8 through the sale of 7 million shares at $5.50 in a follow-on underwritten by Jefferies, Evercore, Deutsche Bank, Wedbush and Oppenheimer. The price is...
12:23 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Voyager, AbbVie to develop anti-tau gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) partnered with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat Alzheimer's disease and other tauopathies. Using Voyager's adeno-associated...

Pages